Ixorib 90 Tablet contains Etoricoxib 90 mg, a selective cyclooxygenase-2 (COX-2) inhibitor used primarily for the management of pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis. By selectively inhibiting the COX-2 enzyme, Ixorib 90 reduces the synthesis of prostaglandins responsible for inflammation and pain, while sparing COX-1, thereby minimizing gastrointestinal side effects commonly seen with non-selective nonsteroidal anti-inflammatory drugs (NSAIDs). This medication is indicated for short-term and long-term treatment of chronic musculoskeletal conditions and acute pain episodes where inflammation is a key component. Ixorib 90 is administered orally, with the dosage tailored according to the severity of symptoms and patient response. It is contraindicated in patients with known hypersensitivity to Etoricoxib or other NSAIDs, active peptic ulcer disease, severe hepatic or renal impairment, and in those with established cardiovascular disease due to an increased risk of thrombotic events. Common adverse effects may include headache, dizziness, hypertension, and gastrointestinal discomfort. Regular monitoring of renal, hepatic, and cardiovascular status is recommended during prolonged therapy. Patients should be advised to report any unusual symptoms promptly to their healthcare provider.